Dtect PGx Pain & Immunology
For drugs used to treat pain and immunological conditions

  • ​Fibromyalgia Agents
  • Muscle Relaxants
  • Opioids
  • Anti-folates
  • Anti-fungals
  • Immunomodulators
  • Immunosupressants​

Dtect PGx Mental Health

For drugs used to treat mental health-related conditions

  • ​Anti-ADHD Agents
  • Anti-seizure / Anti-convulsants
  • Anti-dementia Agents
  • Anti-depressants
  • Anti-psychotics
  • Benzodiazepines

Dtect PGx is re-shaping traditional care by replacing the trial and error method of finding the right drug and or dose for patients. Physicians use PGx testing to provide personalised medicine rather than using the population-based or one size fits all approach.

Dtect PGx may serve as another tool to boost patients’ confidence in the safety and efficacy of prescribed medications. As a result, the process becomes faster and more cost-effective, which decreases the possibility of adverse events caused by the wrong drug choice or dosage.

Dtect PGx screens your DNA using multiple genotyping assays. These assays are run in parallel to identify your genotype for clinically 

informative genetic markers that have been associated with adverse drug reaction risks and drug response.

All genetic markers screened for have been published and experimentally replicated in peer-reviewed scientific journals. This test uses the

latest research technologies and equipment available from the USA.

Advantages of Dtect PGx

Dtect PGx is a pharmacogenomics (PGx) screening test. Pharmacogenomics testing provides insight about a patient’s metabolic pathways. Knowing which pathways are functioning normally or abnormally allows a physician to prescribe medications as intended by the drug manufacturer, select the most appropriate dose, and even the best drug for the patient.

Did you know?

One in four patients is prescribed drugs which could injure them. The risks increase exponentially when more than three medications are prescribed, and when more than six medications are prescribed, the risk exceeds 80%. The US FDA estimates that ADRs are the fourth leading cause of death in US hospitals.

We can now identify patients who have variations or mutations in the genes that control certain drug metabolic processes. Knowing whether a patient is a normal, poor, intermediate or ultra-rapid metaboliser of a medication allows for patient-specific guidance on which medications should be selected or avoided, and the optimal dosage to prescribe.

Dtect PGx screens your DNA for clinically relevant genetic markers which are associated with drug response and adverse drug reaction risks. The test results can identify appropriate medication and suitable drug dosages based on your personal genetic profile.

Types of Dtect PGx Tests

Dtect PGx Cardio & Diabetes 
For drugs used to treat cardiovascular diseases and diabetes

  • Angiotensin ll Receptor Antagonists
  • Anti-anginal Agents
  • Anti-arrhythmics
  • Anti-coagulants
  • Anti-platelets
  • Beta Blockers
  • Statins
  • Sulfonylureas

Dtect PGx Gastro & Urology 
​For drugs used to treat gastrointestinal and urogical disorders

  • Anti-emetics
  • Pronton Pump Inhibitors
  • 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
  • Alpha-Blockers for Benign Prostatic Hyperplasia
  • Antispasmodics for Overactive Bladder
  • Phosphodiesterase Inhibitors for Erectile Dysfuntion​

Dtect PGx will enable you to screen for responses and adverse reactions to nearly 200 commonly prescribed drugs. The results contained within a Dtect PGx report may help you to:

Select medications that suit your patient's genetic profile.

  • Avoid prescribing medications which may result in decreased effectiveness or dangerous reactions.
  • Save time by reducing trial and error.

Each Dtect PGx Report will contain easy to understand information in the form of potential adverse pharmacological effects, indications, and recommendations for each of the drugs included in the test. Evidence levels will either be:

  • Actionable - ready for implementation in a clinical setting based upon guidance provided by international pharmacogenetics expert groups, consortia or regulatory bodies such as FDA, CPIC, DPWG, and EMEA.
  • lnformative - implementation in a clinical setting is at the discretion of the clinician.